Results 181 to 190 of about 1,896,687 (246)
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang +12 more
wiley +1 more source
IL-1 Superfamily Across 400+ Species: Therapeutic Targets and Disease Implications. [PDF]
Wang W +8 more
europepmc +1 more source
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch +13 more
wiley +1 more source
Pregnancy outcomes after maternal and paternal anti-IL-1 treatment exposure in cryopyrin-associated periodic syndromes (CAPS). [PDF]
Satirer Ö +4 more
europepmc +1 more source
Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma
The causes of central nervous system (CNS) hemangioblastoma in Von Hippel–Lindau (vHL) disease are unclear. We used Whole Exome Sequencing (WES) on familial hemangioblastoma to investigate events that underlie tumor development. Our findings suggest that VHL loss creates a permissive environment for tumor formation, while additional alterations ...
Maja Dembic +5 more
wiley +1 more source
Systematic Review of Adverse Events of IL-1 and IL-6 Inhibitor Use in Pediatrics. [PDF]
Perera A, Chugh N, Garcia-Bournissen F.
europepmc +1 more source
74. Comparative Analysis of Acellular Dermal Matrices as Vehicle for Stem Cell Therapy Delivery
Margaret W. Lieb, MD, MS +4 more
doaj +1 more source

